Matt Johnson
About Matt Johnson
Matt Johnson Title
Matt Johnson holds the position of Head of Corporate Development & Strategy at Beyond Cancer, Ltd. In this role, he is responsible for overseeing corporate growth initiatives, strategic direction, and long-term planning for the company.
Matt Johnson at Beyond Cancer, Ltd.
Matt Johnson works at Beyond Cancer, Ltd., where he is heavily involved in advancing cancer treatment technologies. He has played a significant role in the clinical development of ultra-high concentration nitric oxide (UNO) therapy aimed at treating solid tumors.
Matt Johnson Research Co-Authorship
Matt Johnson has co-authored research focused on the effects of ultra-high concentration nitric oxide (UNO) on cancer cells. This work explores the potential of UNO therapy as an effective treatment modality in oncology.
Matt Johnson Clinical Development Involvement
Matt Johnson has participated in the clinical development of UNO therapy for solid tumors. His contributions include involvement in a Phase 1 study evaluating UNO in patients with relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.
Matt Johnson ASCO Annual Meeting Presentation
Matt Johnson has presented his research at the American Society of Clinical Oncology (ASCO) Annual Meeting. This platform is a significant venue for oncology professionals to share innovative research and clinical advancements.